AVXL
ANAVEX LIFE SCIENCES CORP.
NASDAQ · Healthcare · Biotechnology · US
$2.42
+0.41%Sep 17, 2026, 16:17 UTC
Glass Lewis recommended that Anavex Life Sciences stockholders vote the GOLD universal proxy card, supporting PVG Asset Management's call for change by backing two of PVG's director nominees and opposing two incumbent director nominees including the board's current chair.
Source:Sep 14, 2026, 12:30 UTC
Institutional Shareholder Services recommended that Anavex Life Sciences stockholders vote for all six of the company's director nominees on the white proxy card at the 2026 Annual Meeting of Stockholders.
Source:Aug 25, 2026, 16:14 UTC
Anavex Life Sciences announced regulatory progress for its lead drug blarcamesine in Q3 2026.
Source:Aug 25, 2026, 00:00 UTC
Anavex Life Sciences Corp. reported a net income of $7.8 million for Q3 2026, compared with a net loss of $13.2 million in Q3 2025, with diluted EPS of $0.08.